Investigational drug · Phase 2
MT1988
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Clinical High Risk for Psychosis (CHR).
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 8, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "MT1988"
First trial start
2026
Mar 3, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MT1988", any sponsor or status.
Conditions studied
As listed on its trial records.
- Clinical High Risk for Psychosis (CHR)
Approved drugs for the same conditions: Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "MT1988" as an intervention, largest first.
- A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for PsychosisPivotal-lookingRecruiting
Monument Therapeutics LimitedIndustry
NCT07226895 · 150 participants (planned) · Start Mar 3, 2026 · Primary completion Sep 2027
Drug: MT1988 Low Dose; MT1988 High Dose and 1 more · For: Clinical High Risk for Psychosis (CHR)
Sites: Irvine, California; Los Angeles, California; San Francisco, California · 15 sites in all
Monument Therapeutics LimitedIndustry
NCT06728176 · 42 participants · Start Nov 25, 2024 · Primary completion Apr 8, 2025
Drug: MT1988; Placebo · For: Healthy Volunteer
Sites: Glasgow, United Kingdom
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.